Halozyme (NASDAQ: HALO) signs Elektrofi merger agreement and issues PR

Rhea-AI Filing Summary

Halozyme Therapeutics reported that it executed an Agreement and Plan of Merger with Elektrofi, Inc., with the combination to be implemented through Erraid Merger Sub Inc.

The merger agreement is dated September 30, 2025 and names Shareholder Representative Services LLC as shareholder representative. Halozyme issued a press release on October 1, 2025 describing this transaction, which is furnished as Exhibit 99.1 to this report.

Insights

Healthcare M&A analyst

Halozyme is pursuing a merger with Elektrofi under a newly signed agreement.

Halozyme Therapeutics disclosed that it has executed an Agreement and Plan of Merger with Elektrofi, Inc.. The structure uses Erraid Merger Sub Inc. as the merger subsidiary, a common approach in acquisitions where the subsidiary combines with the target and the target becomes part of the acquirer’s group.

The agreement is dated September 30, 2025 and appoints Shareholder Representative Services LLC to act on behalf of Elektrofi’s shareholders, indicating a negotiated transaction with organized shareholder oversight. A press release dated October 1, 2025, furnished as Exhibit 99.1, provides additional detail on the transaction terms and context.

The actual impact for investors depends on the financial and strategic terms described in the press release and any subsequent disclosures, including closing conditions, consideration structure, and integration plans once available.

false 0001159036 0001159036 2025-09-30 2025-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 30, 2025

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Commission File Number 001-32335

Delaware		88-0488686
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
12390 El Camino Real
San Diego
California		92130
(Address of principal executive offices)		(Zip Code)

(858) 794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		HALO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 1, 2025, Halozyme issued a press release announcing the execution of an Agreement and Plan of Merger, dated as of September 30, 2025, by and among Elektrofi, Inc., a Delaware corporation, Halozyme Therapeutics, Inc., a Delaware corporation, Erraid Merger Sub Inc., a Delaware corporation, and Shareholder Representative Services LLC, a Colorado limited liability company (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information set forth under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release of Halozyme Therapeutics, Inc., dated as of October 1, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HALOZYME THERAPEUTICS, INC.
October 1, 2025		By:		/s/ Nicole LaBrosse
		Name:		Nicole LaBrosse
		Title:		Senior Vice President, Chief Financial Officer

FAQ

What transaction did Halozyme (HALO) announce with Elektrofi, Inc.?

Halozyme announced that it executed an Agreement and Plan of Merger with Elektrofi, Inc., using Erraid Merger Sub Inc. to carry out the merger.

When was the Halozyme–Elektrofi merger agreement signed?

The Agreement and Plan of Merger between Halozyme Therapeutics, Inc. and Elektrofi, Inc. is dated September 30, 2025.

Which entities are parties to Halozyme’s merger agreement with Elektrofi?

The agreement is among Elektrofi, Inc., Halozyme Therapeutics, Inc., Erraid Merger Sub Inc., and Shareholder Representative Services LLC as shareholder representative.

How did Halozyme (HALO) communicate details of the Elektrofi merger?

Halozyme issued a press release on October 1, 2025 announcing the execution of the merger agreement, which is furnished as Exhibit 99.1.

What exhibit in Halozyme’s report covers the Elektrofi merger announcement?

The Elektrofi merger announcement is included in Exhibit 99.1, described as a press release of Halozyme Therapeutics, Inc. dated October 1, 2025.

Is Halozyme’s press release about the Elektrofi merger considered filed for liability purposes?

The company states that the information under Item 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act.